Morning or afternoon? timing immunotherapy may boost esophageal cancer outcomes
NCT ID NCT07452601
First seen Mar 08, 2026 · Last updated Jun 19, 2026 · Updated 20 times
Summary
This study is testing whether giving immunotherapy infusions at different times of day changes how well the treatment works for people with a type of esophageal cancer. Ninety patients will receive a combination of the immunotherapy drug adebrelimab plus chemotherapy before surgery. They are split into three groups based on when they get their infusion (morning vs. afternoon). The main goal is to see if timing affects the chance of a complete tumor disappearance after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Tangdu Hospital Affiliated to the Fourth Military Medical University
RECRUITINGXi'an, Shannxi, 710038, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Adebrelimab (immunotherapy) plus nab-paclitaxel and cisplatin (chemotherapy)
What this could lead to
If successful, this could show that timing immunotherapy infusions to a specific time of day improves treatment response and survival for esophageal cancer patients.
What could go wrong
This is a small, early-phase (Phase 2) exploratory study with only 90 participants, so results may not be conclusive or generalizable. The benefit of timing is uncertain and may not translate into better outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.